Aldeyra Therapeutics, Inc.

ALDX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$55,851-$37,543-$62,025-$57,776
Dep. & Amort.$250$263$259$264
Deferred Tax$0$0$0$0
Stock-Based Comp.$7,973$5,753$8,289$7,108
Change in WC$5,913$861-$3,444$7,439
Other Non-Cash-$1,494$340$284$409
Operating Cash Flow-$43,209-$30,326-$56,637-$42,556
Investing Activities
PP&E Inv.$0$0-$16-$8
Net Acquisitions$0$0$16$0
Inv. Purchases-$96,916$0-$92,938$0
Inv. Sales/Matur.$52,000$30,000$63,000$0
Other Inv. Act.$0$0-$16$0
Investing Cash Flow-$44,916$30,000-$29,955-$8
Financing Activities
Debt Repay.-$293-$1,043$0$0
Stock Issued$121$305$1,220$189,812
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$533$0$4,685
Financing Cash Flow-$171-$1,270$1,220$194,496
Forex Effect$0$0$0$0
Net Chg. in Cash-$88,296-$1,596-$85,372$151,933
Supplemental Information
Beg. Cash$142,823$144,419$229,791$77,858
End Cash$54,527$142,823$144,419$229,791
Free Cash Flow-$43,209-$30,326-$56,654-$42,564